Wide range of targeted sequencing panels for tissue and blood samples, including 3-CE marked NGS-based oncopanels detecting up to ~520 biomarkers, and one FDA Breakthrough Device Designation.

QMS supports CLIA/CAP testing, clinical trials under Good Clinical Practice (GCP), and CE-marking product development under Good Manufacturing Practice (GMP).

We have built an efficient and compliant global service chain covering kit shipment, collection, patient billing, and customized and automatic reporting.

Extensive regulatory knowledge of US FDA and EU CE IVDD/IVDR regulations by ex-FDA officer and regulatory affairs professionals.

We have established a comprehensive diagnostic technology system, and have many patented technologies.